Daly James M 4
4 · ACADIA PHARMACEUTICALS INC · Filed Jun 1, 2026
Research Summary
AI-generated summary of this filing
ACADIA (ACAD) Director James M. Daly Receives RSUs, Exercises Options
What Happened
James M. Daly, a director of ACADIA Pharmaceuticals (ACAD), had restricted stock units (RSUs) vest and reported a derivative exercise/conversion on May 29, 2026. The filing shows two award acquisitions (16,004 and 9,311 RSUs; total 25,315 RSUs) reported at $0.00 and a derivative exercise/conversion of 8,107 shares (acquired) with a corresponding disposition of 8,107 derivative shares reported at $0.00. The RSUs vested on May 29, 2026 (the date of the annual meeting) and the filing reports no cash proceeds.
Key Details
- Transaction date: May 29, 2026; Form 4 filed June 1, 2026 (timely within required period).
- Reported transactions: Exercise/conversion (code M) — 8,107 derivative shares acquired; matching disposition of 8,107 derivative shares @ $0.00. Awards/grants (code A) — 16,004 RSUs and 9,311 RSUs acquired @ $0.00.
- Total RSUs vested: 25,315. Reported prices/values: $0.00 for awards and $0.00 for the reported disposition; one acquisition shows N/A for price.
- Shares owned after the reported transactions: not specified in the supplied filing data.
- Relevant footnotes: F1—each RSU equals a contingent right to one share; F2—those RSUs vested in full on May 29, 2026; F3—stock options (if any) vest quarterly over one year; F4—the reporting person elected to defer receipt of the underlying common shares for the RSUs until specified triggers (including up to five years).
Context
- "M" indicates an exercise or conversion of a derivative (e.g., option conversion). The filing shows an acquisition and an immediate disposition of 8,107 derivative shares at $0.00; the Form 4 does not report cash proceeds or further details about the nature of the disposition.
- RSU awards reported at $0.00 are typical (they are compensation awards that convert to shares); here the director has elected to defer receipt of the shares under the company plan until certain events.
- These entries are awards/vesting and a derivative conversion rather than an open-market purchase or sale; awards/vests are informative about compensation and holdings but do not by themselves indicate the director’s intent to buy or sell on the market.
Insider Transaction Report
Form 4
Daly James M
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-05-29+8,107→ 12,148 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-05-29−8,107→ 0 total→ Common Stock (8,107 underlying) - Award
Director Stock Options (Right to Buy)
[F3]2026-05-29+16,004→ 16,004 totalExercise: $21.66Exp: 2036-05-28→ Common Stock (16,004 underlying) - Award
Restricted Stock Units
[F1][F4]2026-05-29+9,311→ 9,311 total→ Common Stock (9,311 underlying)
Footnotes (4)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- [F2]The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
- [F3]The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
- [F4]The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact|2026-06-01